Evicenter
MarkdownMedical informationP&T meetings
Varegacestat (AL102)

Desmoid tumors

Also known as BMS-986115
Manufacturer
Immunome
Launch
Not announced
Last updated
177 sources

Product information and disease descriptionPlace of product in therapyDisease descriptionBurden of Desmoid tumors

Humanistic burden and health-related quality of life

16 evidence topics · 14 sources

Desmoid Tumor Research Foundation natural history study, 2017 to 2023

“Surveys were completed by 399 participants between September 2017 and August 2023. The median age of participants was 38 years; most were female (72%, 288/399), White (84%, 334/399), or resided in North America (86%, 345/399).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote

“Participants with the presence of DT at survey completion reported significantly worse scores for pain, extra-abdominal symptoms, fatigue, physical functioning, and sleep in comparison to those without the current presence of a DT (P < 0.05).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote

“The overall mean Total Symptom Score for all participants was 4.1.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote

“The symptoms and impact of DT in a joint/extremity were reported to be significantly worse for the DTSS Total Symptom Score, DTSS Pain domain, and the DTIS Physical Functioning domain compared with other DT locations (all P < 0.05; Fig. 7a-c).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote

“Conversely, regardless of the current presence of DT, participants reported similar mean scores (P > 0.05) for the DTIS Emotional Impact domain (4.4 with current DT vs. 3.9 without current DT) and all Emotional Impact domain item scores, including Fear of Desmoid Tumor Growth/Recurrence (5.8 vs. 5.2), Anger (3.4 vs. 3.1), Anxiety (4.5 vs. 4.0), and Frustration (4.8 vs. 4.0), except Hopelessness (3.7 vs. 2.7; P = 0.007; data not shown).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote

Health state utility values in the NICE appraisal of nirogacestat

“Although the De‑Fi trial did not collect EQ-5D data, it did collect quality-of-life data using the European Organisation for Research and Treatment of Cancer (EORTC) QLQ-C30.” (opens the source at this quote in a new tab)

“The utility values in the company base case were instead informed by published utility values from people with soft-tissue sarcoma (Shingler et al. 2013).” (opens the source at this quote in a new tab)

“The EAG stated that the utility value for progressed disease in the company base case was implausibly low for people with desmoid tumours (0.263).” (opens the source at this quote in a new tab)

“But, because this data was not provided, the EAG preferred to use utility values based on EQ-5D data from a clinical trial of people with soft-tissue sarcoma (Reichardt et al. 2012). This resulted in a utility value of 0.560 for progressed disease.” (opens the source at this quote in a new tab)

“The company acknowledged that the true utility value of progressed disease was likely to be between the company (0.263) and the EAG (0.560) base cases.” (opens the source at this quote in a new tab)

“At the second committee meeting, the company presented the EORTC QLQ-C30 quality-of-life data from De‑Fi, mapped to EQ-5D using the method from Young et al. (2015). These utilities are considered confidential by the company and so cannot be reported here.” (opens the source at this quote in a new tab)